Diagnostic Accuracy of CT Texture Analysis in Adrenal Masses: A Systematic Review

Filippo Crimi 1,2, Emilio Quaia 1,2, Giulio Cabrelle 1,2, Chiara Zanon 1,2, Alessia Pepe 1,2, Daniela Regazzo 1,3, Irene Tizianel 1,3, Carla Scaroni 1,3 and Filippo Ceccato 1,3,*

1 Department of Medicine DIMED, University of Padova, 35128 Padua, Italy; filippo.crimi@unipd.it (F.C.); emilio.quaia@unipd.it (E.Q.); giulio.cabrelle@gmail.com (G.C.); zanon.chiara.9@gmail.com (C.Z.); alessia.pepe@unipd.it (A.P.); daniela.regazzo@unipd.it (D.R.); irene.tizianel@gmail.com (I.T.); carla.scaroni@unipd.it (C.S.)
2 Institute of Radiology, University-Hospital of Padova, 35128 Padua, Italy
3 Endocrine Disease Unit, University-Hospital of Padova, 35128 Padua, Italy
* Correspondence: filippo.ceccato@unipd.it; Tel.: +39-049-6211323; Fax: +39-049-657391

Abstract: Adrenal incidentalomas (AIs) are incidentally discovered adrenal neoplasms. Overt endocrine secretion (glucocorticoids, mineralocorticoids, and catecholamines) and malignancy (primary or metastatic disease) are assessed at baseline evaluation. Size, lipid content, and washout characterise benign AIs (respectively, <4 cm, <10 Hounsfield unit, and rapid release); nonetheless, 30% of adrenal lesions are not correctly indicated. Recently, image-based texture analysis from computed tomography (CT) may be useful to assess the behaviour of indeterminate adrenal lesions. We performed a systematic review to provide the state-of-the-art of texture analysis in patients with AI. We considered 9 papers (from 70 selected), with a median of 125 patients (range 20–356). Histological confirmation was the most used criteria to differentiate benign from the malignant adrenal mass. Unenhanced or contrast-enhanced data were available in all papers; TexRAD and PyRadiomics were the most used software. Four papers analysed the whole volume, and five considered a region of interest. Different texture features were reported, considering first- and second-order statistics. The pooled median area under the ROC curve in all studies was 0.85, depicting a high diagnostic accuracy, up to 93% in differentiating adrenal adenoma from adrenocortical carcinomas. Despite heterogeneous methodology, texture analysis is a promising diagnostic tool in the first assessment of patients with adrenal lesions.

Keywords: adrenal glands; computed tomography; texture analysis; radiomics

1. Introduction

Adrenal incidentalomas (AIs) are adenalin neoplasms discovered during a procedure not performed for suspected adrenal disease [1,2]. Their prevalence is age dependent (up to 10–15% in adults >60–70 years old), and their detection is increased in recent years, because of the large availability of imaging medical equipment such as computed tomography (CT) and magnetic resonance (MR), resulting in more than 200 CT and 100 MR scans for 1000 people [3].

Overt endocrine secretion (glucocorticoids, mineralocorticoids, and catecholamines, characterising, respectively, Cushing’s syndrome, primary aldosteronism, and pheochromocytoma) should be ruled out in all patients with AI by the measurement of serum cortisol after 1 mg dexamethasone (the overnight suppression test), aldosterone-to-renin ratio, and plasma or urinary metanephrines [2,4,5]. Nevertheless, the majority of them are non-secreting cortical adenomas [1,2].

At the first evaluation, it is also recommended to rule out malignancy [2]. Malignant AIs could be a primary adrenal disease (adrenocortical cancer, ACC, or malignant pheochromocytoma), or metastases, whose prevalence in AIs is 7.5%. A medical history positive
for extra-adrenal cancer or imaging prescription for active cancer are common: Metastatic AI was 22 times more likely during cancer staging [6], and 27% of malignant tumours (especially lung, breast, gastric, liver, and pancreatic cancer) cause adrenal metastasis on autopsy studies [7]. On the contrary, adrenal metastases could be excluded in 96% of AIs by multidisciplinary evaluation in patients affected by colorectal cancer and AIs (10.5% in 500 patients) [8].

The first radiological approach should discriminate benign adenomas from malignant lesions: An attenuation value <10 Hounsfield unit (HU) in unenhanced computed tomography is able to diagnose lipid-rich benign cortical adenomas [2,9]. From a functional point of view, steroid-secreting cells in the adrenal cortex contain a large number of lipids (steroidogenesis comes from cholesterol); therefore, non-functioning benign adrenal adenomas usually contain a high number of lipids [10], recognised by unenhanced CT and quantified with the attenuation value. On the other hand, 30% of benign adrenal adenomas present an attenuation value of >10 HU (lipid-poor adenomas). During contrast-enhanced CT, adenomas typically enhance quickly and show prompt washout, malignant adrenal lesions usually enhance, but they have slower washout. A relative washout (portal HU–delayed HU/portal HU) >40% or an absolute washout (portal HU–delayed HU/portal HU–unenhanced HU) >60% after 15 min indicate a benign lesion [11].

These approaches are not able to characterise all adrenal masses, and adrenal biopsy has a limited role [12]. Large adrenal masses are often heterogeneous for the presence of necrosis, haemorrhage, calcifications, and intracellular lipid content; therefore, neither CT nor MR scans are able to define their nature. Recently, an emerging field of radiology, called radiomics, uses image-based texture analysis from CT and MR to provide quantitative parameters that may be useful to measure the heterogeneity of tumours [13,14].

The aim of the present review is to provide an up-to-date, state-of-the-art application of texture analysis in patients with AI.

2. Results

All the studies identified by the literature search were observational retrospective, and their setting was a university hospital. According to selection criteria, nine papers were considered in this systematic review, reported in Table 1. Their QUADAS-2 is reported in Table 2.
| First Author | Year of Publication | Study Type | Number of Patients | Type of Adrenal Lesions | Unenhanced CT/Contrast-Enhanced CT | Number of Radiologists Involved | Observers Blinded to Clinical/Pathological Data | Reference Standard | Texture Analysis Software | Spatial Scaling Factors | Number of Textural Features Selected (Unenhanced CT/Contrast-Enhanced CT) | Number of Observers Involved | Observers Blinded to Radiomics/Pathology Data | Reference Cutoff (Functioning vs. Non-functioning) | Pooled AUC of the Study (Benign vs. Malignant Lesion) |
|-------------|-------------------|------------|-------------------|-------------------------|----------------------------------|---------------------------------|---------------------------------|----------------------------|----------------------|-----------------------------|---------------------------------|---------------------------------|---------------------|------------------------------------------------|------------------------------------------------|---------------------------|
| Shi B       | 2018              | Observational retrospective | 225               | Lipid poor adenomas, metastases, pheochromocytoma | +/-                             | 2                               | Yes                             | Histology                  | TexRAD               | 0, 2, 3, 4, 5, 6             | 5/4                             | 0.81                             |
| Yu HS       | 2020              | Observational retrospective | 125               | Benign (not specified), metastases | -/+                             | 1                               | Yes                             | Histology                  | TexRAD               | 0, 2, 3, 4, 5, 6             | 0/36                             | 0.89                             |
| Elmohr MM   | 2019              | Observational retrospective | 54                | Adenomas, adrenocortical carcinomas | +/-                             | 2                               | Yes                             | Histology                  | PyRadiomics          | NA                           | 3/2                             | 0.86                             |
| Ho LM       | 2019              | Observational retrospective | 20                | Lipid poor adenomas, metastases, adrenocortical carcinomas | +/-                             | 1                               | NA                             | Histology or radiological features (rapid size increase) | Lesion Tool | NA                           | 9/18                             | 0.85                             |
| Shoemaker K | 2018              | Observational retrospective | 356               | Adrenocortical carcinomas, adenomas, benign (not specified), haemorrhages, adrenal hyperplasia, lymphoma, malignant (not specified), metastases, myelolipomas, neuroendocrine tumours, pheochromocytomas | NA                              | NA                             | NA                             | NA                        | C++ program          | NA                           | 37                              | 0.78 0.93 (functioning vs. non-functioning) 1 (calcified vs. non-calcified) |
| Andersen MB  | 2021              | Observational retrospective | 160               | Benign (not specified), metastases of lung tumours (adenocarcinoma, squamous cell carcinoma, neuroendocrine tumours, unclassified NSCLC or SCLC) | -/+                             | 2                               | Yes                             | Histology                  | TexRAD               | NA                           | 0/25                             | 0.67                             |
| Li X        | 2021              | Observational retrospective | 204               | Benign (not specified), malignant (not specified) | +/-                             | 1                               | NA                             | Histology                  | HRGSDP method       | NA                           | 5/5                             | NA                               |
| First Author | Year of Publication | Study Type | Number of Patients | Type of Adrenal Lesions | Unenhanced CT/Contrast-Enhanced CT | Number of Radiologists Involved | Observers Blinded to Clinical/Histopathological Data | Reference Standard | Texture Analysis Software | Spatial Scaling Factors | Number of Textural Features Selected (Unenhanced CT/Contrast-Enhanced CT) | Pooled AUC of the Study (Benign vs. Malignant Lesion) |
|--------------|---------------------|------------|-------------------|------------------------|------------------------------------|-------------------------------|---------------------------------|-------------------|---------------------------|------------------------|-----------------------------------------------------------|---------------------------------------------|
| Moawad AW    | 2021                | Observational retrospective | 40               | Benign (not specified), metastases, adrenocortical carcinomas | +/+                              | 2                            | NA                              | Histology     | PyRadiomics              | NA                     | 1/3                                           | 0.85                                       |
| Torresan F   | 2021                | Observational retrospective | 30               | Adenomas, benign incidentalomas, adrenocortical carcinomas | +/+                              | 2                            | Yes                             | Histology or follow-up | PMOD          | NA                     | 16/24                                              | NA                                           |

+: performed; −: not performed.

Table 2. Quality Assessment of Diagnostic Accuracy Studies (QUADAS) version 2 evaluation of the papers selected for the systematic review.
The median number of patients included in the studies was 125 (range 20–356).

In six studies, histopathological examination was used as a gold standard reference to confirm the malignant or benign nature of the adrenal tumours [15–20]. Two studies used a combination of histopathological and follow-up data [21,22]. In one study, the gold standard employed to discriminate between benign versus malignant lesions was unclear [23].

Six studies included adrenal metastases among malignant adrenal lesions [15,16,18–20,22,23]. Two studies focused the analysis on the differential diagnosis between adrenal cortisol lesions (ACC and adenomas) [17,21].

Notably, two studies [15,23] included pheochromocytomas, which are usually diagnosed by serum or urine fractionated metanephrines instead of imaging.

Three studies included only CT scans after injection of intravenous contrast medium [16,18,20], while the others reported the employment of both unenhanced and contrast-enhanced CT images for texture analysis.

The most frequently used software for texture analysis was TexRAD (n = 3) [15,16,18], followed by PyRadiomics (n = 2) [17,20].

Four papers analysed the whole volume of the adrenal lesions [17,21–23], while five focused only on a single region of interest (ROI) drawn in an axial slice [15,16,18–20].

In five studies, the ROIs of the adrenal lesions were drawn by two radiologists in consensus [15,17,18,20,21], while in three other studies, only one radiologist was involved [16,19,22].

Three groups collected textural features applying an image filtration technique with a Laplacian of Gaussian spatial bandpass filter that used different spatial scaling filters (SSF), in order to enhance features of different sizes and intensity variation in the adrenal lesions [15,16,18].

Different texture features were reported to be significantly different between benign and malignant adrenal lesions (first- and second-order parameters). First-order statistics describe the properties of individual pixels, while second-order statistics also consider the spatial interdependency or co-occurrence of two pixels at their specific positions.

All studies but two [19,21], drew receiver-operating characteristic (ROC) curves to calculate the accuracy of the textural parameters in discriminating benign from malignant lesions. The pooled median area under the ROC curve (AUC) was 0.85 (range 0.67–0.89).

In one study [23], the authors focused on the accuracy of CT texture analysis in differentiating secreting from non-secreting masses (the AUC was 0.93) and calcified versus non-calcified lesions (AUC was 1.00).

Notably, four studies found the mean attenuation value at unenhanced CT scan among the parameters that showed a statistically significant difference between the benign and malignant adrenal masses; one reported a higher mean densitometry of the benign lesion [15] while the other three showed a higher mean densitometry of the malignant lesions [17,21,22].

Focusing on the two studies that compared adrenal adenoma and adrenocortical carcinomas, the results showed a very good performance of the CT texture analysis in differentiating benign from malignant lesions, with an AUC of 0.86 reported by Elmohr et al. [17] and an accuracy of 93% reported by Torresan et al. [21] (Figures 1 and 2).
Some steroid precursors/metabolites (especially tetrahydro-11-deoxycortisol and 17-hydroxyprogesterone) are peculiar in the setting of adrenocortical malignancy [25]; their specific steroid fingerprint, second to immature steroidogenesis. Despite a large interindividual heterogeneity, a ‘steroidomic’ approach is able to identify ACC and differentiate it from adenomas [26], achieving in selected cases >90% sensitivity and specificity [25].

During clinical practice, several physicians are facing a large and increasing number of patients with AIs, due to the availability of imaging facilities (especially CT and MR) [3].

### 3. Discussion

During clinical practice, several physicians are facing a large and increasing number of patients with AIs, due to the availability of imaging facilities (especially CT and MR) [3].
At the first evaluation, it is important to determine the non-secreting and benign behaviour of the adenoma. In the case of the non-conclusive first approach, a multidisciplinary evaluation is suggested, in order to personalise the approach with nuclear/functional imaging or second-level dynamic endocrine tests [24].

A novel and emerging approach to characterise the behaviour of adrenal lesions is the measurement of steroid precursors using mass spectrometry, which allows the identification of several steroids and intermediate patterns [25]. Malignant lesions have a specific steroid fingerprint, secondary to immature steroidogenesis. Despite a large interindividual heterogeneity, a ‘steroidomic’ approach is able to identify ACC and differentiate it from adenomas [26], achieving in selected cases >90% sensitivity and specificity [25]. Some steroid precursors/metabolites (especially tetrahydro-11-deoxycortisol and 17-hydroxypregnenolone) are peculiar in the setting of adrenocortical malignancy [25]; their combination with tumour size and lipid content is able to predict adenoma behaviour [27]. One of the drawbacks of such a steroidomic approach is its limited availability (only in selected academic centres with mass spectrometry facilities) and time-consuming analysis.

According to several guidelines and recent papers [1,2,28–30], small size and a high lipid content (<4 cm in size and <10 HU attenuation value) are accepted as markers of a benign lesion. Nonetheless, up to 30% of AIs do not fulfil the well-established criteria of a benign lesion, and novel approaches are needed. Recently, image-based texture analysis from CT and MR provides quantitative parameters that may be useful to measure the presence of necrosis, haemorrhage, calcifications, and intracellular lipid content, allowing to differentiate benign from malignant tumours [13,14,31–33].

From 2018 to 2021, several papers regarding texture analyses in patients with adrenal lesions have been published. After our systematic review, only nine works presented an adequate level of evidence and were analysed. Unfortunately, the reported data were heterogeneous to such an extent that a meta-analysis was not computable because true/false and positive/negative cases were not reported in an adequate number of studies.

Our results show that texture analysis has a good accuracy in differentiating benign from malignant adrenal lesions (pooled AUC 0.85); moreover, it performed even better in the differentiation between cortical lesions (adenomas and ACC). It is not a minor concern, because cortisol secretion can be overt or subclinical in an adenoma or a carcinoma; therefore, an endocrine differentiation of cortical masses is not always feasible.

Some groups focused on the identification of secreting adrenal lesions and included pheochromocytomas among the cases analysed. However, in clinical practice, when a physician is facing the question of whether the lesion is benign or not, the study of the endocrine function of a lesion is a pivotal tool. As a matter of fact, the adrenal cortex is able to synthesise and secrete steroids, and the adrenal medulla is deputed to the production of catecholamines, and biochemical tests are very accurate in identifying these hormonal products. Therefore, the study of the endocrine secretion must proceed close to radiological evaluations, and the use of texture analysis for hormonal production seems to be a time-consuming application due to the wide availability of very accurate laboratory examinations. Among the nine papers selected for the systematic review, only two were able to reply to a research question that can fulfil the population–intervention–comparison–outcome (PICO) model [34]. In the authors’ opinion, an answer to the proper research question of texture analysis addressing ‘the distinction between adrenal cortical adenoma and carcinoma’ can be found in the studies by Elmohr et al. [17] and Torresan et al. [21].

Notably, different studies underlined the good performance of CT texture analysis performed in the unenhanced scan. These data are of much interest mainly for two reasons: the first is that they highlight the application of texture analysis also in the field of the newly discovered AIs since many times the examination performed is an unenhanced CT scan performed for other reasons than a suspected adrenal pathology, while the second reason is that in the future, the characterisation of the adrenal masses with texture analysis will spare the contrast medium injection in these patients, allowing a reduced risk of allergic reaction and a negative impact on renal function [35,36].
Radiomics and, in particular, CT texture analysis can represent a more accessible and less time-consuming tool to differentiate benign from malignant adrenal lesions, compared with steroidomic approaches. Almost all centres can afford to perform a CT examination on a patient with AI, and many different software programs are available to extract textural features from CT images. The easy applicability of this new technique brought different study groups to test the efficacy and accuracy of texture analysis in adrenal lesions. Since the expanding use of radiomic in this context, the aim of the present review is to summarise the body of evidence in the literature in order to provide a guide for future application of this method of analysis.

Only selected studies considered a histological confirmation of the adrenal mass. This is a critical matter because, in clinical practice, the adrenal can be the site of a large series of primary and secondary, either benign or malignant, diseases [37]. Therefore, adrenalectomy is of utmost importance, at least to obtain the confirmation of the adenoma. In clinical practice, the use of adrenal biopsy is limited to selected cases, especially in patients with a history of extra-adrenal malignancy [12]. Lastly, we must consider that the results we are facing are not all derived from the same CT scanner, and it has been reported that different types of images acquisition can increase the variability in the densitometry value of each pixel or voxel, affecting the reproducibility of the results obtained by each study and, therefore, the usefulness of texture analysis [38].

The 18-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET), alone or combined with CT or MR, could be useful to characterise malignant forms. An adrenal mass is likely malignant when the uptake of 18-FDG is higher than that of the liver. However, false positives (sarcoidosis, tuberculosis, lipid-poor or cortisol-secreting adenomas, and pheochromocytomas) or negatives (haemorrhage or necrosis are common in malignant lesions) must be considered [39–43]. Finally, PET is considered second-line imaging because it is performed in selected cases in a limited number of centres; on the contrary, CT is widely available (therefore, an effort for texture analysis in CT can produce a significant result).

There are several limitations. Firstly, the low number of studies published in the literature and the huge variety of techniques and parameters used to test the accuracy of texture did not allow us to perform a meta-analysis. However, despite its limitations, the pooled AUC can be a good indicator of the performance of this new radiological technique. Secondly, the histopathological diagnoses of benign and malignant lesions varied consistently, and such heterogeneity could have affected the results. Finally, the CT scanning protocols were different among the studies included in the review and, therefore, is a source of variability that can affect the comparison of the results.

In conclusion, from the data collected in this systematic review, texture analysis appears as a new promising diagnostic tool in the adrenal tumoral pathologies; nevertheless, further prospective multicentric studies are needed to confirm its role in the clinical setting.

4. Materials and Methods

4.1. Search Strategy

We used three search engines (PubMed, Web of Science, and Scopus), from inception through to July 2021, for a literature search based on the PRISMA criteria [44]. We used the following terms and their variants in the title, abstract and keyword fields, and MeSH fields where available, adapting the search syntax where necessary: ‘adrenal AND computed tomography-CT-AND texture analysis; adrenal AND computed tomography-CT-AND texture analysis AND radiomics’.

The references we included in the review were also searched manually for papers not identified by the initial literature search.

Exclusion criteria were the following: (I) articles not written in English; (II) studies containing aggregated data or data duplicated from previously published works; (III) review articles; (IV) letters; (V) case reports; (VI) editorials. No restrictions were placed on study design or population.
4.2. Review Protocol and Data Extraction

Three authors (G.C., C.Z., and F.Cr.) independently screened all titles and abstracts generated by analysing the databases. Afterwards, the same authors screened the full texts of all the relevant papers identified according to the inclusion criteria. Any disagreement regarding article suitability for the inclusion in the review was fixed by discussion or, failing this, by referral to a senior author (F.Ce.).

Among 70 papers obtained from the literature search, 9 reports published between 2018 and 2021 met the inclusion criteria (Figure 3).

![Figure 3. Retrieval flowchart to obtain study data for systematic review.](image)

Data from these studies were extracted using a standardised pro forma in Microsoft Excel (Redmond, WA, USA). The information extracted from each study included author, year of publication, study design, number of cases, and main findings.

All the studies were scored based on the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) version 2 [45]. Discrete variables were expressed as means ± standard deviations, or medians and interquartile ranges (IQR), as appropriate. Categorical data were described as absolute numbers and percentages.

Author Contributions: Conceptualisation, F.C. (Filippo Ceccato) and F.C. (Filippo Crimi); methodology, F.C. (Filippo Crimi) and G.C.; software, C.Z.; validation, C.S., D.R. and I.T.; formal analysis, G.C., A.P. and C.Z.; data curation, G.C. and A.P.; writing—original draft preparation, F.C. (Filippo...
Ceccato) and F.C. (Filippo Crimi); writing—review and editing, E.Q. and C.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding. The APC was funded by an academic grant from the Resident School of Radiology.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All data are available in the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Terzolo, M.; Stigliano, A.; Chiodini, I.; Loli, P.; Furlani, L.; Arnaldi, G.; Reimondo, G.; Pia, A.; Toscano, V.; Zini, M.; et al. AME Position Statement on Adrenal Incidentaloma. *Eur. J. Endocrinol.* **2011**, *164*, 851–870. [CrossRef]

2. Fassnacht, M.; Dekkers, O.M.; Else, T.; Baudin, E.; Berruti, A.; de Krijger, R.R.; Haak, H.R.; Mihai, R.; Assie, G.; Terzolo, M. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in Collaboration with the European Network for the Study of Adrenal Tumors. *Eur. J. Endocrinol.* **2018**, *179*, G1–G46. [CrossRef]

3. Papanicolas, I.; Woskie, L.R.; Jha, A.K. Health Care Spending in the United States and Other High-Income Countries. *JAMA* **2018**, *319*, 1024–1039. [CrossRef]

4. Lenders, J.W.M.; Duh, Q.-Y.; Eisenhofer, G.; Gimenez-Roqueplo, A.-P.; Grebe, S.K.G.; Murad, M.H.; Naruse, M.; Pacak, K.; Young, W.F. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. *J. Clin. Endocrinol. Metab.* **2010**, *95*, R65–R80. [CrossRef]

5. Ebbehoj, A.; Li, D.; Kaur, R.J.; Zhang, C.; Singh, S.; Li, T.; Atkinson, E.; Achenbach, S.; Khosla, S.; Arlt, W.; et al. Epidemiology of Adrenal Tumours in Olmsted County, Minnesota, USA: A Population-Based Cohort Study. *Lancet Diabetes Endocrinol.* **2020**, *8*, 894–902. [CrossRef]

6. Shi, B.; Zhang, G.M.Y.; Xu, M.; Jin, Z.Y.; Sun, H. Distinguishing Metastases from Benign Adrenal Masses: What Can CT Texture Analysis Do? *Acta Radiol.* **2019**, *60*, 1553–1561. [CrossRef]

7. Elmohr, M.M.; Fuentes, D.; Habra, M.A.; Bhosale, P.R.; Qayyum, A.A.; Gates, E.; Morshid, A.I.; Hazle, J.D.; Elsayes, K.M. Machine Learning-Based Texture Analysis for Differentiation of Large Adrenal Cortical Tumours on CT. *Clin. Radiol.* **2019**, *74*, 818.e1–818.e7. [CrossRef]

8. Anderson, M.B.; Bodtger, U.; Andersen, I.R.; Thorup, K.S.; Ganeshan, B.; Rasmussen, F. Metastases or Benign Adrenal Lesions in Patients with Histopathological Verification of Lung Cancer: Can CT Texture Analysis Distinguish? *Eur. J. Radiol.* **2021**, *138*, 109664. [CrossRef]

9. Boland, G.W.; Lee, M.J.; Gazelle, G.S.; Halpern, E.F.; McNicholas, M.M.; Mueller, P.R. Characterization of Adrenal Masses Using Unenhanced CT: An Analysis of the CT Literature. *Am. J. Roentgenol.* **1998**, *171*, 201–204. [CrossRef]

10. Peña, C.S.; Boland, G.W.L.; Hahn, P.F.; Lee, M.J.; Mueller, P.R. Characterization of Indeterminate (Lipid-Poor) Adrenal Masses: Use of Washout Characteristics at Contrast-Enhanced CT. *Radiology* **2000**, *217*, 798–802. [CrossRef]

11. Bancos, I.; Tamhane, S.; Shah, M.; Delivanis, D.A.; Alahdab, F.; Arlt, W.; Fassnacht, M.; Murad, M.H. DIAGNOSIS OF ENDOCRINE DISEASE: The Diagnostic Performance of Adrenal Biopsy: A Systematic Review and Meta-Analysis. *Eur. J. Endocrinol.* **2016**, *175*, R65–R80. [CrossRef]

12. Yu, H.; Parakh, A.; Blake, M.; McDermott, S. Texture Analysis as a Radiomic Marker for Differentiating Benign from Malignant Adrenal Tumors. *J. Comput. Assist. Tomogr.* **2020**, *44*, 766–771. [CrossRef]
43. Groussin, L.; Bonardel, G.; Silvéra, S.; Tissier, F.; Coste, J.; Abiven, G.; Libé, R.; Bienvenu, M.; Alberini, J.L.; Salenave, S.; et al. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: A prospective study in 77 operated patients. J. Clin. Endocrinol. Metab. 2009, 94, 1713–1722. [CrossRef]

44. Moher, D.; Shamseer, L.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 Statement. Syst. Rev. 2015, 4, 1. [CrossRef]

45. Whiting, P.F. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann. Intern. Med. 2011, 155, 529–536. [CrossRef]